The first R&D Network in 2015 will take a closer look at antibody drug conjugates and treatment options, the use in clinical treatment and exciting new conjugated antibodies in pipeline.
The registration is now closed. Send an email to Marthe Brovold Løberg if you would like to join or have to cancel.
The seminar and light refreshments afterwards are free of charge, but please note that we will issue a no-show fee. Let us know 24 hours prior to the event, if you can not come.
We look forward to an interesting meeting.
Member companies Takeda Nycomed and Roche Norge AS kindly support the R&D Network
PROGRAM /Download program
|14:00–14:15||Registration and coffee|
|14:15–14:30||Welcome and introduction- Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet|
|14:30–15:00||International key note speaker:“Development of Antibody Drug Conjugates in hematologic malignancies”- Dr Rodney B. Smith MD, Senior International Medical Director, Roche|
|15:00–15:40||International key note speaker:”Antibody-drug conjugates and new treatment options”- Petter Veiby, PhD, global head of BioTherapeutics, Oncology DDU at Takeda Pharmaceuticals International, US.Q&A session10 min coffee break|
|16:00–16:30||Clinical perspectives:“Antibody-drug conjugates in treatment of lymphoma cancer patients”- Alexander Fosså, MD, Dept. of Oncology, OUS Radiumhospitalet|
|16:30–17:00||The biotech perspective:“Phase I study with new radioimmunoconjugate in indolent non-Hodgkin`s lymphomas. A Nordic Nanovector study”- Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet|
|17:00–18:00||Networking session with light refreshments|